BPA Call 36E79721A0023-36C24122N0160
Award Date
11/24/21
Potential Completion Date
11/23/22
Potential Value
$494K
Federal Agency
Veterans Integrated Service Network 1
Awardee
Regeneron Pharmaceuticals Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Temecula, CA 92591, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This delivery order from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 1 to Regeneron Pharmaceuticals Inc. is for $148,228.56 to supply the drug EVKEEZA. It was awarded on September 8, 2021 under the Pharmaceuticals and Drugs Federal Supply Schedule with a completion date of October 31, 2021. The pricing is firm fixed price. This order was placed against Regeneron's GSA Schedule contract for pharmaceutical products and therapeutic...
<p>This is a Blanket Purchase Agreement (BPA) call order awarded by the U.S. Department of Veterans Affairs (VA) to Eisai Inc., a foreign-owned, for-profit manufacturer of pharmaceutical goods. The contract is for express pharmacy ordering of pharmaceuticals for fiscal year 2017 and has a ceiling value of $136,596.21. The contract is not set aside and is under the VA's Pharmaceutical and Drugs Federal Supply Schedule (FSS-61-IB) vehicle. The place of performance is Westwood, New Jersey.</p>
This is a firm fixed-price delivery order contract awarded by the Department of Veterans Affairs (VA) to APL Sales I LLC, a subsidiary of Apellis Pharmaceuticals, Inc. The contract is for the delivery of EMPAVELI 1080 MG, a complement C3 inhibitor used to treat paroxysmal nocturnal hemoglobinuria, a rare blood disorder. The contract has a ceiling value of $26,218.96 and a completion date of February 27, 2025. The contract was awarded under the VA's Federal Supply Schedule (FSS) contract for...
This is a firm fixed price delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to APL Sales I LLC, a subsidiary of Apellis Pharmaceuticals, Inc. The contract is for the supply of the drug EMPAVELI 1080 MG, used to treat paroxysmal nocturnal hemoglobinuria, a rare blood disorder. The contract has a ceiling value of $25,831.04 and a performance period ending on June 18, 2024. This delivery order contract is issued under APL Sales I LLC's existing Federal Supply Schedule...
This is a firm fixed price delivery order awarded by the Department of Veterans Affairs (VA) Veterans Integrated Service Network 5 to APL Sales I LLC, a subsidiary of Apellis Pharmaceuticals, Inc. The $25,831.04 order is for the delivery of the drug EMPAVELI to VA facilities in Pittsburgh, Pennsylvania. This delivery order falls under APL Sales I LLC's Federal Supply Schedule contract under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, which has a ceiling value of $225,000 and runs through...
This is a $5,565,000,000.00 Firm Fixed Price definitive contract awarded by the Joint PEO Chemical and Biological Defense, a defense agency, to Regeneron Pharmaceuticals Inc. for the production of a COVID-19 therapeutic in support of Operation Warp Speed. The contract has no set-aside and is scheduled for completion by July 31, 2022. Regeneron Pharmaceuticals Inc. is a for-profit manufacturer of goods that has expanded its services from supplying specific pharmaceutical products to large-scale...
This is a firm fixed price Delivery Order awarded by the Veterans Health Administration (VHA), which is part of the U.S. Department of Veterans Affairs (VA), to APL Sales I LLC, a subsidiary of Apellis Pharmaceuticals, Inc. The $25,831.04 order is for the delivery of 1,080 mg doses of the drug EMPAVELI to a VA medical facility in Pittsburgh, Pennsylvania. EMPAVELI is used to treat paroxysmal nocturnal hemoglobinuria, a rare blood disorder. APL Sales I LLC holds multiple contracting vehicles with...
The Department of Veterans Affairs Veterans Health Administration awarded a $25,506.96 delivery order contract to APL Sales I LLC, a subsidiary of Apellis Pharmaceuticals, Inc., to provide EMPAVELI 1080 MG. The contract was awarded under the Pharmaceuticals and Drugs Federal Supply Schedule, also known as FSS-61-IB, which is a multiple award schedule managed by the General Services Administration. Place of performance will be in Pittsburgh, Pennsylvania over a period of performance from August...
The Department of Veterans Affairs Veterans Health Administration awarded a $25,506.96 delivery order contract to APL Sales I LLC, a subsidiary of Apellis Pharmaceuticals, Inc., to provide EMPAVELI 1080 MG. The contract was awarded under the Pharmaceuticals and Drugs GSA Schedule, also known as FSS-61-IB, and will be performed in Pittsburgh, Pennsylvania over a one week period concluding on January 4, 2024. As the parent company produces drugs to treat rare diseases, this contract is likely...
This federal contract award is a Blanket Purchase Agreement (BPA) call for pharmaceutical products issued by the Department of Veterans Affairs (VA) to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The contract has a ceiling value of $99,785.07 and a completion date of September 28, 2017. The contract is a firm fixed-price agreement under the VA's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. This contract facilitates the procurement of critical...